Form 4: Cytokinetics Director Robert Harrington Reports Stock and Option Transactions

Director Robert Harrington reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Summary

• On May 14, 2025, Robert Arthur Harrington, a director of Cytokinetics Inc., reported transactions involving the company's securities.
• Harrington acquired 7,333 restricted stock units (RSUs) and 10,880 non-qualified stock options.
• The RSUs will vest in one installment on the earlier of the one-year anniversary of the grant date or the date of the issuer's annual meeting of stockholders for the subsequent calendar year, contingent upon continuous service as a director.
• The stock options will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier of the one-year anniversary of the grant date or the date of the issuer's annual meeting of stockholders for the subsequent calendar year, contingent upon continuous service as a director.
• Harrington also disposed of 22,315 shares of common stock.
• Following these transactions, Harrington beneficially owns 22,315 shares of common stock and 10,880 derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The acquisition of stock options and RSUs could be seen as positive, but the disposal of shares is a negative. The overall impact is likely minimal.

Positives

• The acquisition of RSUs and stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Negatives

• The disposal of 22,315 shares of common stock by a director could be interpreted negatively by some investors.

Risks

• The vesting of RSUs and stock options is contingent upon the director's continuous service, which introduces a risk if the director were to leave the board.
• Market conditions could impact the value of the stock options, potentially affecting their attractiveness to the director.

Future Outlook

The vesting of RSUs and stock options is contingent upon the director's continuous service and the occurrence of specific events (one-year anniversary or annual meeting).

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for insights into management's sentiment and potential future actions.

Stakeholder Impact

• Shareholders may react to the reported transactions, potentially influencing the stock price.
• The transactions have no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Cytokinetics, Director, Harrington, Stock Options, RSUs, Common Stock, Beneficial Ownership, Form 4, Securities